Relevance of screening for Chagas and viral hepatitis in Bolivian migrants

Irene Losada Galván^{*1}, Giuseppe Gariup², Aina Casellas¹, Carme Subirà¹, Alex Almuedo-Riera^{1,3}, Daniel Camprubí¹, Natalia Rodríguez-Valero¹, Joaquim Gascón¹, Jose Muñoz¹, María Jesús Pinazo^{*1}

(1) ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain. (2) Internal Medicine, Hospital Clinic, Barcelona. (3) Internal Medicine, Hospital General de Granollers, Barcelona

* Both authors as corresponding authors

irenelosada@gmail.com & mariajesus.pinazo@isglobal.org

Abstract

Objectives: given the scarcity of data regarding prevalence of various infectious diseases in Latin-American countries, our study aims to assess the burden of *T.cruzi*, *S.stercoralis*, HIV and viral hepatitis in Latin-American migrants, with a focus on Bolivian migrants.

Methods: we performed a retrospective observational study of 565 screening evaluations on adults (≥ 18 years) carried out at our referral International Healthcare service in Barcelona. We reviewed structured clinical records and microbiological results of patients attended between February 2012 and April 2015.

Results: the median 35 years old and 74% were women. Bolivian origin accounted for 87% of the screened population. We found a 48% prevalence of *T.cruzi*, 16% of *S.stercoralis*, 0.2% of HIV, 92% of HAV, 0.2% HBV and 0.2% HCV.

Conclusions: these results support the relevance of the screening of *T. cruzi* and *S. stercoralis* in Bolivian migrants, but challenge the pertinence of systematic screening of HBV in this population.

Author summary

In response to the challenge of detecting diseases not previously present in host countries, screening programs have been implemented for migrants based on the probability of having certain diseases depending on their country of origin and / or migratory route. This increased risk is very clearly established in some cases such as *Trypanosoma cruzi* infection (the cause of Chagas disease) in people from Latin America; especially from Bolivia. In recent years screening recommendations for *Strongyloides stercoralis* in this population was proven necessary. Current recommendations regarding systematic screening for hepatitis B establish the relevance of screening based on the probability of the disease in the 2% population of origin. Since there are no reliable and up to date data regarding prevalence of hepatitis B virus in Bolivia, we aimed to analyze data available for migrants from Bolivia in Spain.

Our results support the importance of screening for *T. cruzi* and *S. stercoralis* in patients from Bolivia. However, our data show a much lower prevalence of this hepatitis B virus (0.2%) than the 2% threshold that would justify systematic screening, so we question the relevance of screening for hepatitis B virus in this population in the absence of other risk factors.

Introduction

The increase in global migratory movements in recent decades implies new challenges for health professionals and policy makers, especially regarding the need to diagnose and treat previously non-endemic pathologies in the host countries. One of the diseases that best illustrates this challenge is Chagas disease, caused by chronic infection by *Trypanosoma cruzi*

parasite.

It is estimated that 6-7 million people worldwide are infected with *T. cruzi*, mainly in Latin America (LA), where it causes more than 10000 deaths per year(1). The first reports of Chagas disease in Europe were published in the early 1980s, with a marked increase around 2000, along with the rising flow of migrants from LA to Europe(2–4). From 2007 onwards, a number of initiatives both at national and international levels have been implemented in order to increase awareness and provide better care to potentially affected populations (5). These aim for better control vertical transmission (congenital, from mother to fetus)(6) and transmission by infected blood and organ donors(7,8). Such initiatives include screening programs, which are often the first contact of the migrant with the health system in host countries. Thus, they represent an opportunity for a thorough medical examination and complementary tests. The indication of performing these diagnostic tests derives from the estimated prevalence for each risk group, using the country of origin in the absence of other known risk factors (9,10).

The relevance of conducting Chagas disease screening in Latin American migrants is based on epidemiological data from the countries of origin as well as data from recipient countries: WHO estimates a global prevalence of 1% in LA countries(11), with great variations within the different countries in the region (highest prevalence in Bolivia 6.1% and Paraguay 2.1%). Data from non-endemic areas shows similar results: a meta-analysis(12) on prevalence of Chagas disease in Europe estimated a prevalence of 4.2%, also with important variations according to country of origin, with the highest prevalence among Bolivian immigrants (18%). In addition, there are studies in favor of the cost-effectiveness of screening for Chagas disease in this context(13,14).

Another well-established indication for screening would be *Strongyloides stercoralis*, with an estimated prevalence of 370 million worldwide (15) and regional LA country-specific prevalence ranging from 1 to 73%(16,17). *S. stercoralis* chronic infection is usually

asymptomatic, but it can develop into a severe and highly lethal disease in the context of immunosuppression(18). The association of *T.cruzi* infection with a two-fold increase in the odds of strongyloidiasis (19) support this combined strategy of screening (*T.cruzi* - *S.stercoralis*) in LA migrants.

WHO estimates that in 2015, 257 million persons were living with chronic Hepatitis B Virus (HBV) infection in the world, 68% in African and Western Pacific regions(20). Chronic HBV infection is usually asymptomatic, but 20-30% of patients with chronic VHB infection will develop complications (including liver cirrhosis and hepatocellular carcinoma). Testing for chronic HBV infection meets established public health screening criteria(21). In the absence of specific risk factors such as blood transfusion recipients before 1991, injectable drug users, men who have sex with men; a geographic-based screening is performed based on the HBV prevalence of the countries of origin. Before 2008 the HBV prevalence threshold was established at 8% (high endemicity countries), that was then lowered to a 2% prevalence (medium endemicity) in the updated recommendations of the CDC(22). Ever since there is a broad consensus on the relevance and cost-effectiveness of screening for hepatitis B in people from countries with prevalence greater than 2%(23). However this figure is currently under discussion: a study performed in the United States argued that it would be cost-effective screening in populations with prevalence as low as 0,3%(24). Both European(25–27) and American (28–30) guidelines recommend screening in migrants coming from countries with a HBV prevalence of 2% or higher. However, the discussion of the screening threshold becomes futile when epidemiological studies on which the recommendations are based by each country are scarce, not updated and often conflicting. The WHO estimates an overall prevalence in the region of the Americas between 0.4 and 1.6%(31), with 7-12 million Latin Americans carrying HBV chronic infection(32). In the case of Bolivia, there is conflicting evidence with regard to its HVB infection prevalence. A meta-analysis(33) showed a prevalence of between 0.1 and 6%, but its baseline data oscillate between 1987 and 2008, with a total sample of 1930 patients.

Another systematic review (34) estimates a prevalence of HBV in Bolivia of 0.44% based on 4 studies (1357 patients).

The scenario of chronic infection with hepatitis C virus (HCV) is very different. The prevalence of this disease is higher in Spain (1.7%) compared to the prevalence in Latin American countries (1.1%-1.3%, Bolivia 0.9%) (27,35). Therefore, given the low prevalence in LA countries, screening indication would be given in any case by risk factors different from the country of origin. However, some authors argue that HCV screening should be performed anytime HBV screening is indicated for another reason.

According to 2016 ECDC epidemiological assessment(36), estimates of total number of migrants infected with HCV or HBV might be an overestimation, since prevalence is often lower in migrants compared to the prevalence of the country of origin.

Data on serologic prevalence of viral hepatitis in LA migrants in Spain is scarce and often conflicting with reports from other countries in Europe. A report from a Tropical Medicine Centre in Madrid (37) found 1.6% chronic HBV infection in LA migrants. These results are similar to a 1.6% and 1.2% chronic HBV infection from a referral center (38) and a primary care study (39) both in Barcelona; as opposed to a 0.6% overall prevalence found on another study in the UK(40).

Considering the scarcity of data of the previously stated entities in LA migrants, our study aims to assess the burden of these infectious diseases in Latin-American migrants attending a referral International Healthcare service in Barcelona, with a focus on Bolivian migrants. We intend to contribute our data to those of other migrant cohorts in high income countries, given that they are a useful source of information on the prevalence of various infectious diseases when reliable data from the countries of origin are not available. We evaluate the number of chronic infections in the target population in comparison with that of their countries of origin in order to assess the pertinence of the systematic screening in this population.

Methods

This retrospective observational study was performed at the International Health department of the Hospital Clinic of Barcelona. We reviewed medical records from all patients at risk of *T. cruzi* infection attending our unit between February 2012 and April 2015.

In our clinic we perform screening evaluations on adults (age 18 or older) who come from Latin American Countries. They come to the clinic either spontaneously, counseled by friends or relatives or referred by their physician. The first visit consists of an interview in which epidemiological information is collected as well as relevant medical history. A physical examination is performed and diagnostic tests are requested according to current screening guidelines.

Epidemiological data include age, sex, country of origin, year of arrival in Spain, risks factors for *T. cruzi* acquisition (rural area, adobe housing, contact with triatomine vector, blood transfusions, mother affected with Chagas disease) and risk factors for hepatitis (blood transfusions, unprotected sexual relationships). The usual screening workup includes a blood cell count, general biochemistry, serologies for *T. cruzi*, *S. stercoralis*, HIV, HBV and HCV. HAV was tested according to physician preference. Stool samples are collected for parasitological examination.

Screening of Chagas was performed with a chemiluminescent microparticle immunoassay (ARCHITECT Chagas®, Abbott)(41). A positive result was confirmed with a conventional ELISA with recombinant antigens (CHAGAS ELISA IgG+IgM, Vircell)(42) as per WHO recommendations for diagnosis(43). *S. stercoralis* infection was diagnosed by direct visualization of ova in stool or a positive one-step sandwich-format immunoassay for the qualitative detection of IgG-class antibodies to *Strongyloides stercoralis* antigen (Strongyloides ELISA, SciMedx)(44). Detection of hepatitis B virus surface antigen (HBsAgII, Advia Centaur) (45), antibody against hepatitis B virus core (HBc Total, Advia Centaur) (46) and surface antigen (antiHBs 2, Advia Centaur)(47)

were used to assess HBV status. Active infection was considered if HBsAg was positive; vaccination if HBsAg was negative, HBsAb positive and HBcAb negative, and cured infection if HBsAg is negative and HBsAb and HBcAb positive. Accurate classification was not always possible since not all the individuals in the cohort had a complete serology. Antibodies against hepatitis A (HAV Total, Advia Centaur)(48) and C (HCV, Advia Centaur)(49) viruses were used to detect passed HAV infection and to screen for chronic HCV infection. Screening of HIV was made by a chemiluminometric immunoassay of antigen binding microparticles that is used to detect antibodies against human immunodeficiency virus type 1, including subtype O, and / or type 2 (HIV 1 / O / 2 Enhanced Assay, Avia Centaur)(50).

Data were presented as frequencies and median (interquartile range, IQR) for discrete and continuous variables, respectively. Proportions were compared using Chi-squared test or Fisher's exact test if the application conditions of the former where not met. Medians were compared between groups using Wilcoxon Rank Sum test. Significance was set at 0.05. The analysis was carried out using Stata 15 (StataCorp. 2017)(51).

This study was approved by the ethics committee for medical research of Hospital Clinic Barcelona with reference number HCB/2018/0521. All analyzed data were previously anonymized.

Results

Over the study period, 565 individuals were screened for *T. cruzi* and other infectious diseases. The median (IQR) age was 35 (29 - 42) years old and 74% were women. Median (IQR) time elapsed from their arrival to the country and this screening was eight (7-10) years. Demographic characteristics and presence of risk factors for *T. cruzi* infection of the study population compared by *T. cruzi* results are shown in Table 1. Four hundred and ninety-five Bolivian patients were screened, accounting for 87% of the screened population. The

171 remaining 71 individuals came from other Latin American countries, with Argentina as the next
172 most numerous country of origin (21, 4%).

173 **Table 1.** Demographic characteristics and *T. cruzi* risk factors

Variable		T.cruzi serology		Total	p-value
		Negative	Positive		
Demographic characteristics					
Gender (female) ¹		193 / 292 (66.1%)	203 / 273 (74.4%)	396 / 565 (70.1%)	0.0321 ²
Age ³		33.5 (27 - 41) [292]	37 (32 - 44) [273]	35 (29 - 42) [565]	< 0.0001 ⁴
Age ¹	0-25	56 (19.2%)	11 (4.0%)	67 (11.9%)	< 0.0001 ²
	26-40	162 (55.5%)	156 (57.1%)	318 (56.3%)	
	>40	74 (25.3%)	106 (38.8%)	180 (31.9%)	
	Total	292 (100.0%)	273 (100.0%)	565 (100.0%)	
Preconsultation time (years) ³		8 (6 - 10) [292]	8 (7 - 10) [273]	8 (7 - 10) [565]	0.3832 ⁴
Risk Factors for Chagas disease					
Lived in rural areas ¹		210 / 292 (71.9%)	245 / 273 (89.7%)	455 / 565 (80.5%)	< 0.0001 ²
Adobe housing ¹		212 / 290 (73.1%)	244 / 273 (89.4%)	456 / 563 (81.0%)	< 0.0001 ²
Blood products recipients ¹		11 / 290 (3.8%)	19 / 270 (7.0%)	30 / 560 (5.4%)	0.0885 ²
Blood donors ¹		8 / 292 (2.7%)	3 / 273 (1.1%)	11 / 565 (1.9%)	0.1584 ²

Screening son/daughter of positive mother ¹	48 / 280 (17.1%)	32 / 270 (11.9%)	80 / 550 (14.5%)	0.0785 ²
--	---------------------	---------------------	---------------------	---------------------

1: n (Column percentage); 2: Chi-squared test; 3: Median (IQR) [n]; 4: Wilcoxon Rank Sum test;

5: Fisher's exact test

Chagas disease. *T. cruzi* was positive in 273 participants (48%) of the screened individuals.

Among them, there was a greater presence of known risk factors for *T. cruzi* infection as

residence in rural area (90%, $p < 0.0001$), adobe housing (89%, $p < 0.0001$), but no differences

were found regarding the receipt of blood products. Out of 80 patients whose mothers had

confirmed positive serology for *T. cruzi*, 32 (40%; 95%CI: 29-52%) were also positive for *T. cruzi*

but without significative difference.

We also compared *T. cruzi* positivity in relation to other infectious diseases, with results shown

in Tables 2 and 3.

Table 2. Hepatitis B virus screening by *T. cruzi* results

Variable		<i>T. cruzi</i> serology		Total	p-value
		Negative	Positive		
HBV ¹	Negative	151 (58.3%)	125 (53.0%)	276 (55.8%)	0.0008 ²
	Positive	1 (0.4%)	0 (0.0%)	1 (0.2%)	
	Immune by past infection	7 (2.7%)	15 (6.4%)	22 (4.4%)	
	Immune by vaccination	37 (14.3%)	15 (6.4%)	52 (10.5%)	
	Indeterminate	0 (0.0%)	3 (1.3%)	3 (0.6%)	

	Incomplete	63 (24.3%)	78 (33.1%)	141 (28.5%)	
	<i>Total</i>	<i>259 (100.0%)</i>	<i>236 (100.0%)</i>	<i>495 (100.0%)</i>	

186 HBV: hepatitis B virus

187 1: n (Column percentage); 2: Fisher's exact test

188 Negative: HBsAg-, HBsAb-, HBcAb-; Positive: HBsAg+; Immune by past infection: HBsAg-,

189 HBsAb+, HBcAb+; Immune by vaccination: HBsAg-, HBsAb+, HBcAb-; Indeterminate: HBsAg-,

190 HBsAb-, HBcAb+

191

192 **Table 3.** Other infectious diseases by *T. cruzi* results

Variable		<i>T. cruzi</i> serology		Total	p-value
		Negative	Positive		
Screening for other infectious diseases					
HIV	Negative	270 (99.6%)	253 (100.0%)	523 (99.8%)	1.0000 ³
	Positive	1 (0.4%)	0 (0.0%)	1 (0.2%)	
	<i>Total</i>	<i>271 (100.0%)</i>	<i>253 (100.0%)</i>	<i>524 (100.0%)</i>	
HAV IgG ¹	Negative	15 (11.5%)	5 (3.9%)	20 (7.8%)	0.0229 ²
	Positive	115 (88.5%)	122 (96.1%)	237 (92.2%)	
	<i>Total</i>	<i>130 (100.0%)</i>	<i>127 (100.0%)</i>	<i>257 (100.0%)</i>	
HCV ¹	Negative	234 (100.0%)	223 (99.6%)	457 (99.8%)	0.4891 ³

	Positive	0 (0.0%)	1 (0.4%)	1 (0.2%)	
	<i>Total</i>	<i>234 (100.0%)</i>	<i>224 (100.0%)</i>	<i>458 (100.0%)</i>	
Strongyloides stercoralis ¹	Negative	178 (87.7%)	152 (76.8%)	330 (82.3%)	0.0123 ⁵
	Positive	23 (11.3%)	42 (21.2%)	65 (16.2%)	
	Indeterminate	2 (1.0%)	4 (2.0%)	6 (1.5%)	
	<i>Total</i>	<i>203 (100.0%)</i>	<i>198 (100.0%)</i>	<i>401 (100.0%)</i>	

HIV: Human immunodeficiency virus; HAV: hepatitis A virus; HBV: hepatitis B virus; HCV:

hepatitis C virus.

1: n (Column percentage); 2: Chi-squared test; 3: Fisher's exact test

HIV. Serologic test for HIV was performed in 93% of the study population, with one positive result on a man who had sex with men, without other risk factors.

Hepatitis A virus. A serologic test for HAV was performed in 45% of the study population. A positive HAV was significantly more frequent among individuals who were also positive for *T. cruzi*, with an overall prevalence of 92%. (Table 3)

Hepatitis B virus. A serologic test for HBV was performed in 88% (495) of the study population. However, there was insufficient information for HBV classification on 141 individuals (28%). Among those with a complete serology, there was a 7% prevalence of positive serology for HBV (either by chronic or immune by past infection) –see Table 2-, with one case (0.2%) of chronic HBV. This patient had been previously diagnosed on a routine test in Bolivia. She

denied risky sexual practices, transfusions or parenteral drug use. However, she reported several accidental punctures when he practiced dentistry in Bolivia. The remaining 93% had a negative serology for HBV or were immune by vaccination. The prevalence of chronic/past infection was significantly higher among individuals who were also positive for *T. cruzi*. Table 4 shows demographic characteristics and microbiological results of Bolivian patients by HBV.

Table 4. Results from Bolivian migrants with respect to HBV results

Variable		HBV		Total
		Negative or Immune by vaccination	Positive or Immune by past infection	
Gender (female) ¹		195 / 287 (67.9%)	13 / 22 (59.1%)	208 / 309 (67.3%)
Age ²		36 (28 - 43) [287]	36 (33 - 46) [22]	36 (29 - 43) [309]
Age ¹	36 (12.5%)	0 (0.0%)	36 (11.7%)	36 (12%)
	158 (55.1%)	16 (72.7%)	174 (56.3%)	174 (56%)
	93 (32.4%)	6 (27.3%)	99 (32.0%)	99 (32%)
	287 (100.0%)	22 (100.0%)	309 (100.0%)	309 (100%)
Preconsultation time (years) ²		8 (7 - 9) [287]	8 (7 - 10) [22]	8 (7 - 9) [309]
Screening for other infectious diseases				
HIV ¹	Negative	284 (100.0%)	22 (100.0%)	306 (100.0%)
HAV IgG ¹	Negative	9 (6.8%)	3 (27.3%)	12 (8.3%)
	Positive	124 (93.2%)	8 (72.7%)	132 (91.7%)
	Total	133 (100.0%)	11 (100.0%)	144 (100.0%)

HCV ¹	Negative	257 (99.6%)	20 (100.0%)	277 (99.6%)
	Positive	1 (0.4%)	0 (0.0%)	1 (0.4%)
	<i>Total</i>	<i>258 (100.0%)</i>	<i>20 (100.0%)</i>	<i>278 (100.0%)</i>
<i>Strongyloides stercoralis</i> serology ¹	Negative	146 (50.9%)	11 (50.0%)	157 (50.8%)
	Positive	30 (10.5%)	5 (22.7%)	35 (11.3%)
	Indeterminate	5 (1.7%)	0 (0.0%)	5 (1.6%)
	Missing	106 (36.9%)	6 (27.3%)	112 (36.2%)
	<i>Total</i>	<i>287 (100.0%)</i>	<i>22 (100.0%)</i>	<i>309 (100.0%)</i>

HIV: Human immunodeficiency virus; HAV: hepatitis A virus; HCV: hepatitis C virus.

1: n (Column percentage); 2: Median (IQR) [n]

Hepatitis C virus. A serologic test for HCV was performed in 81% of the study population.

There was one positive result from a patient who was also positive for *T. cruzi*, but negative for HBV and HIV. This patient was initially screened for HCV in 2014 with a negative result. During follow-up, an elevation of transaminases advised a new a serological study, which was positive for HCV. She had not traveled since 2014; so acute HCV infection (genotype 1a) acquired in Spain between February and March 2016 was suspected. Her elastography showed no fibrosis and was successfully treated with Sofosbuvir/Ledipasvir in 2017 (viral load undetectable since then).

Strongyloides stercoralis. A serologic test and/or stool sample for parasite examination was obtained in 71% of the study population, with an overall prevalence of 16%. This prevalence of

Strongyloides stercoralis infection was significantly higher in patients who were also positive for *T. cruzi* (Table 3).

Discussion

The aim of this study was to describe the prevalence of different infectious diseases in Bolivian and other Latin-American migrants attending a referral International Health service in order to establish more accurate screening protocols according to international recommendations.

First we should acknowledge that the vast majority of the screened individuals were from Bolivia, and coming from several areas with a high migratory tradition (52). This limits the generalization of the results to the Latin American community as a whole, but provides with a robust source of information about the Bolivian community in our context. Hence, most of our analysis will apply only to Bolivian migrants.

Another relevant finding is a prevalence for *T. cruzi* infection as high as 48% of the screened population. This is probably due to various reasons. First, the majority of the screened population was from highly endemic areas in Bolivia (with an expected prevalence of 18%)(12).

Secondly, some patients already know about their diagnosis before coming to our clinic.

Moreover, patients with a positive result for *T. cruzi* might be more prone to follow the general advice of inviting their relatives to the screening program. Thus, this unusually high prevalence of Chagas disease might be influenced by community and family clusters that share risk factors for the disease. These risk factors include having lived in a house made of adobe and having lived in rural areas, which are both significant risk factors for *T. cruzi* in this study population.

Interestingly, in our cohort, having received blood products was not statistically associated with a higher risk of *T. cruzi* infection. This might be due to the relative small number of patients who did receive some blood product in their countries of origin, but it might also be an early outcome of the blood bank controls that were implemented in Bolivia (43,54). In light of these results and others in other non-endemic countries (3,12), we cannot stress enough

the need for standardized screening programs for *T. cruzi* in Latin American migrants. An early *T. cruzi* diagnosis allows the individual evaluation and adequacy of the support treatment according to the clinical stage. In addition, it enables the evaluation of the indication of antiparasitic treatment (55,56) in order to reduce the likelihood of progression of the disease as well as being an instrument for interrupting transmission, especially in non-endemic areas through the treatment of women of childbearing age (57–59).

In agreement with previous work (19), we found a high prevalence of **Strongyloidiasis** and an association with *T. cruzi* infection. This further supports maintaining a combined screening strategy of these two pathogens.

The observed high **hepatitis A virus** prevalence and its association with *T. cruzi* infection might be due to shared risk factors in terms of low socio economic status and deficient hygienic conditions, although the most frequent means of transmission are essentially different for these two diseases. However, this observation could be conditioned by the fact of having HAV data only of 45.5% of the patients.

Our results show very low chronic **hepatitis B virus** prevalence (0.2%), although up to 7% of the screened population was immune by past infection. This prevalence of chronic HBV would not justify a systematic screening program in these patients. The most accepted threshold is 2%(25–30), well above the most ambitious estimates which recommend screening in communities with a prevalence of 0.3% (24). However, it is possible that the selection of this cohort of patients is not random within Bolivia and that we are facing a healthy migrant bias. Moreover, the fact that patients are screened for HBV a median of 8 years after they arrive, further jeopardizes the probability of diagnosing acute infections. Acute infections acquired prior to departure or in the host country might be wrongly classified due to this long period between arrival and HBV screening. Moreover, no complete serological information was available for almost one third of patients, which constitutes one of the main limitations of the study. There are no updated data on prevalence of HBV or vaccination coverage since its

introduction in 2000 (60). It would be necessary to have up-to-date and robust evidence on the epidemiology of HBV in Bolivia in order to improve the targeted screening of this disease in the absence of other risk factors for HBV. In any case, this scenario of young and healthy patients is common in countries that host migrant population; and therefore it is the basis on which estimates of the necessary screening can be made, in the absence of reliable epidemiological data from the countries of origin.

Due to the negative gradient of the prevalence of **hepatitis C virus** in Spain with respect to Bolivia, the systematic screening of this disease in the absence of other risk factors would not be granted. However, as some authors recommend, HCV serology is sometimes performed when requesting other serologies, such as HBV or HIV in young people who are sexually active due to the risk of acquisition in the host country. Our results confirm the relevance of this strategy in both the prevalence of HCV and HIV.

Conclusions

This work supports the relevance of the screening of *T.cruzi* and strongyloides in people from Bolivia. Hepatitis A virus is endemic and the vast majority of people have positive serology due to past infection, therefore screening is not recommended. According to available evidence, the systematic screening of HCV and HIV is not recommended, with the exception of making at least one determination in sexually active persons. On the other hand, this work questions the relevance of systematic HBV screening in Bolivian migrants given its low prevalence. Epidemiological studies are urgently needed to clarify the situation of HBV in Bolivia in order to direct efforts both inside and outside its borders.

305 Funding

306 The team is supported by the Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR)
 307 (2016SGR924) and by the Tropical Disease Cooperative Research Network (RICET)
 308 (RD16/0027/0004). ISGlobal is a member of the Centres de Recerca de Catalunya (CERCA)
 309 Programme, Government of Catalonia (Spain).

310 Conflict of interest

311 The funders had no role in study design, data collection and analysis, decision to publish, or
 312 preparation of the manuscript. None of the authors declares having conflicts of interest.

313

314 Bibliography

- 315 1. WHO | Chagas disease (American trypanosomiasis). WHO [Internet]. 2017 [cited 2017
316 Jun 8]; Available from: <http://www.who.int/mediacentre/factsheets/fs340/en/>
- 317 2. Schmunis GA. Epidemiology of Chagas disease in non-endemic countries: the role of
318 international migration. Mem Inst Oswaldo Cruz [Internet]. 2007 Oct 30 [cited 2019 Jan
319 18];102 Suppl 1:75–85. Available from:
320 <http://www.ncbi.nlm.nih.gov/pubmed/17891282>
- 321 3. Gascon J, Bern C, Pinazo M-J. Chagas disease in Spain, the United States and other non-
322 endemic countries. Acta Trop [Internet]. 2010 Jul [cited 2017 Jun 8];115(1–2):22–7.
323 Available from: <http://linkinghub.elsevier.com/retrieve/pii/S0001706X09001995>
- 324 4. Pérez de Ayala, Ana; Pérez-Molina, José Antonio; Navarro, Miriam; López-Vélez R.
325 Enfermedad de Chagas en personas procedentes de latinoamérica residentes en
326 España. Minist Sanid y Política Soc [Internet]. 2009 [cited 2018 May 15]; Available from:
327 <https://www.msssi.gob.es/profesionales/saludPublica/prevPromocion/promocion/migracion/docs/enfermedadChagas.pdf>
328
- 329 5. Albajar-Viñas P, Jannin J. The hidden Chagas disease burden in Europe. Euro Surveill
330 [Internet]. 2011 [cited 2018 Mar 31];16(38). Available from:
331 www.eurosurveillance.org:pii=19975.
- 332 6. Howard EJ, Xiong X, Carlier Y, Sosa-Estani S, Buekens P. Frequency of the congenital
333 transmission of *Trypanosoma cruzi*: a systematic review and meta-analysis. BJOG
334 [Internet]. 2014 Jan [cited 2019 Jan 18];121(1):22–33. Available from:
335 <http://doi.wiley.com/10.1111/1471-0528.12396>
- 336 7. Bern C, Montgomery SP, Katz L, Caglioti S, Stramer SL. Chagas disease and the US blood
337 supply. Curr Opin Infect Dis [Internet]. 2008 Oct [cited 2019 Jan 18];21(5):476–82.
338 Available from: <https://insights.ovid.com/crossref?an=00001432-200810000-00006>
- 339 8. Huprikar S, Bosserman E, Patel G, Moore A, Pinney S, Anyanwu A, et al. Donor-Derived
340 *Trypanosoma cruzi* Infection in Solid Organ Recipients in the United States, 2001–2011.
341 Am J Transplant [Internet]. 2013 Sep [cited 2019 Jan 18];13(9):2418–25. Available from:
342 <http://www.ncbi.nlm.nih.gov/pubmed/23837488>
- 343 9. Pottie MCISc K, Greenaway C, Feightner J, Welch V, Swinkels MHSc H, Rashid M, et al.
344 Evidence-based clinical guidelines for immigrants and refugees for summary of
345 recommendations and clinical considerations. CMAJ [Internet]. 2011 [cited 2018 Dec
346 13];(12):183. Available from: [www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.090313/-](http://www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.090313/-/DC1)
347 /DC1
- 348 10. Van Der Werf J, Derrough T, Duffell E, Pharris A, Suk J, De H, et al. Public health
349 guidance on screening and vaccination for infectious diseases in newly arrived migrants
350 within the EU/EEA Public health guidance on screening and vaccination for infectious
351 diseases in newly arrived migrants within the EU/EEA [Internet]. 2018 [cited 2018 Dec
352 13]. Available from: [https://www.ecdc.europa.eu/en/news-events/ecdc-issues-](https://www.ecdc.europa.eu/en/news-events/ecdc-issues-migrant-screening-and-vaccination-guidance)
353 migrant-screening-and-vaccination-guidance
- 354 11. Cochrane A, Evlampidou I, Irish C, Ingle SM, Hickman M. Hepatitis B infection
355 prevalence by country of birth in migrant populations in a large UK city. J Clin Virol
356 [Internet]. 2015 Jul [cited 2017 Dec 20];68:79–82. Available from:
357 <http://www.ncbi.nlm.nih.gov/pubmed/26071342>

- 358 12. Requena-Méndez A, Aldasoro E, de Lazzari E, Sicuri E, Brown M, Moore DAJ, et al.
359 Prevalence of Chagas disease in Latin-American migrants living in Europe: a systematic
360 review and meta-analysis. Rodrigues MM, editor. PLoS Negl Trop Dis [Internet]. 2015
361 Feb 13 [cited 2017 Jun 8];9(2):e0003540. Available from:
362 <http://dx.plos.org/10.1371/journal.pntd.0003540>
- 363 13. Requena-Méndez A, Bussion S, Aldasoro E, Jackson Y, Angheben A, Moore D, et al. Cost-
364 effectiveness of Chagas disease screening in Latin American migrants at primary health-
365 care centres in Europe: a Markov model analysis. Lancet Glob Heal [Internet]. 2017 Apr
366 [cited 2017 Jun 8];5(4):e439–47. Available from:
367 <http://www.ncbi.nlm.nih.gov/pubmed/28256340>
- 368 14. Sicuri E, Muñoz J, Pinazo MJ, Posada E, Sanchez J, Alonso PL, et al. Economic evaluation
369 of Chagas disease screening of pregnant Latin American women and of their infants in a
370 non endemic area. Acta Trop [Internet]. 2011 May [cited 2019 Jan 18];118(2):110–7.
371 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21396345>
- 372 15. Bisoffi Z, Buonfrate D, Montresor A, Requena-Méndez A, Muñoz J, Krolewiecki AJ, et al.
373 Strongyloides stercoralis: a plea for action. Lammie PJ, editor. PLoS Negl Trop Dis
374 [Internet]. 2013 May 9 [cited 2018 Apr 30];7(5):e2214. Available from:
375 <http://dx.plos.org/10.1371/journal.pntd.0002214>
- 376 16. Schär F, Trostorf U, Giardina F, Khieu V, Muth S, Marti H, et al. Strongyloides
377 stercoralis: Global Distribution and Risk Factors. PLoS Negl Trop Dis [Internet]. 2013
378 [cited 2018 Apr 30];7(7):e2288. Available from:
379 <http://www.ncbi.nlm.nih.gov/pubmed/23875033>
- 380 17. BUONFRATE D, MENA MA, ANGHEBEN A, REQUENA-MENDEZ A, MUÑOZ J, GOBBI F, et
381 al. Prevalence of strongyloidiasis in Latin America: a systematic review of the literature.
382 Epidemiol Infect [Internet]. 2015 Feb 3 [cited 2018 Apr 30];143(03):452–60. Available
383 from: <http://www.ncbi.nlm.nih.gov/pubmed/24990510>
- 384 18. Buonfrate D, Requena-Mendez A, Angheben A, Muñoz J, Gobbi F, Van Den Ende J, et al.
385 Severe strongyloidiasis: a systematic review of case reports. BMC Infect Dis [Internet].
386 2013 Feb 8 [cited 2019 Jan 18];13(1):78. Available from:
387 <http://bmcinfctdis.biomedcentral.com/articles/10.1186/1471-2334-13-78>
- 388 19. Puerta-Alcalde P, Gomez-Junyent J, Requena-Mendez A, Pinazo MJ, Álvarez-Martínez
389 MJ, Rodríguez N, et al. High prevalence of S. Stercoralis infection among patients with
390 Chagas disease: A retrospective case-control study. Arndt MB, editor. PLoS Negl Trop
391 Dis [Internet]. 2018 Jan 31 [cited 2018 Apr 30];12(1):e0006199. Available from:
392 <http://www.ncbi.nlm.nih.gov/pubmed/29385128>
- 393 20. WHO. Global Hepatitis Report [Internet]. 2017 [cited 2017 Nov 29]. Available from:
394 <http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?ua=1>
- 395 21. Wilson J, Jungner G, Organization WH. The principles and practice of screening for
396 disease. 1966 [cited 2018 May 1]; Available from:
397 http://apps.who.int/iris/bitstream/10665/208882/1/WHO_PA_66.7_eng.pdf
- 398 22. Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, et al.
399 Recommendations for identification and public health management of persons with
400 chronic hepatitis B virus infection. MMWR Recomm reports Morb Mortal Wkly report
401 Recomm reports [Internet]. 2008 Sep 19 [cited 2018 Apr 30];57(RR-8):1–20. Available
402 from: <http://www.ncbi.nlm.nih.gov/pubmed/18802412>

- 403 23. Hahné SJ, Veldhuijzen IK, Wiessing L, Lim T-A, Salminen M, Van De Laar M. Infection
404 with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-
405 effectiveness of screening. BMC Infect Dis [Internet]. 2013 [cited 2017 Nov 27];13:1.
406 Available from: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716892/pdf/1471-
407 2334-13-181.pdf](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716892/pdf/1471-2334-13-181.pdf)
- 408 24. Eckman MH, Kaiser TE, Sherman KE. The cost-effectiveness of screening for chronic
409 hepatitis B infection in the United States. Clin Infect Dis [Internet]. 2011 Jun 1 [cited
410 2018 Apr 30];52(11):1294–306. Available from: [https://academic.oup.com/cid/article-
411 lookup/doi/10.1093/cid/cir199](https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/cir199)
- 412 25. Tavoschi L, Duffel E, Adlhoch C, Aspinall E, Hutchinson S, Goldberg D. Hepatitis B and C
413 testing activities, needs, and priorities in the EU/EEA. [cited 2017 Nov 22]; Available
414 from: [https://ecdc.europa.eu/sites/portal/files/documents/HepatitisBC-testing-in-EU-
415 May2017.pdf](https://ecdc.europa.eu/sites/portal/files/documents/HepatitisBC-testing-in-EU-May2017.pdf)
- 416 26. Hepatitis B and C testing: people at risk of infection | Guidance and guidelines | NICE.
417 [cited 2017 Nov 22]; Available from: <https://www.nice.org.uk/guidance/PH43>
- 418 27. Epidemiological assessment of hepatitis B and C among migrants in the EU/EEA. [cited
419 2017 Nov 22]; Available from:
420 [https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/epidemi-
421 ological-assessment-hepatitis-B-and-C-among-migrants-EU-EEA.pdf](https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/epidemiological-assessment-hepatitis-B-and-C-among-migrants-EU-EEA.pdf)
- 422 28. LeFevre ML, U.S. Preventive Services Task Force. Screening for Hepatitis B Virus
423 Infection in Nonpregnant Adolescents and Adults: U.S. Preventive Services Task Force
424 Recommendation Statement. Ann Intern Med [Internet]. 2014 Jul 1 [cited 2017 Dec
425 15];161(1):58. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24863637>
- 426 29. Pottie K, Mayhew AD, Morton RL, Greenaway C, Akl EA, Rahman P, et al. Prevention
427 and assessment of infectious diseases among children and adult migrants arriving to
428 the European Union/European Economic Association: a protocol for a suite of
429 systematic reviews for public health and health systems. BMJ Open [Internet]. 2017 Sep
430 11 [cited 2017 Sep 15];7(9):e014608. Available from:
431 <http://www.ncbi.nlm.nih.gov/pubmed/28893741>
- 432 30. Abara WE, Qaseem A, Schillie S, McMahon BJ, Harris AM, High Value Care Task Force of
433 the American College of Physicians and the Centers for Disease Control and Prevention.
434 Hepatitis B Vaccination, Screening, and Linkage to Care: Best Practice Advice From the
435 American College of Physicians and the Centers for Disease Control and Prevention.
436 Ann Intern Med [Internet]. 2017 Dec 5 [cited 2017 Dec 14];167(11):794. Available from:
437 <http://www.ncbi.nlm.nih.gov/pubmed/29159414>
- 438 31. WHO | Monitoring and evaluation for viral hepatitis B and C: recommended indicators
439 and framework. WHO [Internet]. 2016 [cited 2018 Apr 30]; Available from:
440 <http://www.who.int/hepatitis/publications/hep-b-c-monitoring-evaluation/en/>
- 441 32. Zampino R, Boemio A, Sagnelli C, Alessio L, Adinolfi LE, Sagnelli E, et al. Hepatitis B virus
442 burden in developing countries. World J Gastroenterol [Internet]. 2015 Nov 14 [cited
443 2017 Dec 20];21(42):11941. Available from:
444 <http://www.ncbi.nlm.nih.gov/pubmed/26576083>
- 445 33. Kowdley K V., Wang CC, Welch S, Roberts H, Brosgart CL. Prevalence of chronic hepatitis
446 B among foreign-born persons living in the United States by country of origin.
447 Hepatology. 2012;56(2):422–33.

- 448 34. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide
449 prevalence of chronic hepatitis B virus infection: a systematic review of data published
450 between 1965 and 2013. *Artic 1546 www.thelancet.com Funding World Heal Organ*
451 [Internet]. [cited 2017 Nov 29]; Available from: [https://www-clinicalkey-com.m-](https://www-clinicalkey-com.m-hdoct.a17.csinet.es/service/content/pdf/watermarked/1-s2.0-S014067361561412X.pdf?locale=es_ES)
452 [hdoct.a17.csinet.es/service/content/pdf/watermarked/1-s2.0-](https://www-clinicalkey-com.m-hdoct.a17.csinet.es/service/content/pdf/watermarked/1-s2.0-S014067361561412X.pdf?locale=es_ES)
453 [S014067361561412X.pdf?locale=es_ES](https://www-clinicalkey-com.m-hdoct.a17.csinet.es/service/content/pdf/watermarked/1-s2.0-S014067361561412X.pdf?locale=es_ES)
- 454 35. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and
455 genotype distribution of the hepatitis C virus infection. [cited 2017 Nov 27]; Available
456 from: [https://www-clinicalkey-com.m-](https://www-clinicalkey-com.m-hdoct.a17.csinet.es/service/content/pdf/watermarked/1-s2.0-S0168827814005261.pdf?locale=es_ES)
457 [hdoct.a17.csinet.es/service/content/pdf/watermarked/1-s2.0-](https://www-clinicalkey-com.m-hdoct.a17.csinet.es/service/content/pdf/watermarked/1-s2.0-S0168827814005261.pdf?locale=es_ES)
458 [S0168827814005261.pdf?locale=es_ES](https://www-clinicalkey-com.m-hdoct.a17.csinet.es/service/content/pdf/watermarked/1-s2.0-S0168827814005261.pdf?locale=es_ES)
- 459 36. Epidemiological assessment of hepatitis B and C among migrants in the EU/EEA.
- 460 37. Monge-Maillo B, López-Vélez R, Ferrere-González F, Norman FF, Martínez-Pérez Á,
461 Pérez-Molina JA. Screening of Imported Infectious Diseases Among Asymptomatic Sub-
462 Saharan African and Latin American Immigrants: A Public Health Challenge. *Am J Trop*
463 *Med Hyg* [Internet]. 2015 Apr 1 [cited 2017 Dec 20];92(4):848–56. Available from:
464 <http://www.ncbi.nlm.nih.gov/pubmed/25646257>
- 465 38. Pahissa A, Salvador F, Sánchez-Montalvá A, Bocanegra C, Molina I, Sulleiro E. Screening
466 for Imported Diseases in an Immigrant Population: Experience from a Teaching Hospital
467 in Barcelona, Spain. *Am J Trop Med Hyg* [Internet]. 2014 Dec 3 [cited 2018 Jan
468 8];91(6):1277–81. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25331805>
- 469 39. Valerio L, Barro S, Pérez B, Roca C, Fernández J, Solsona L, et al. [Seroprevalence of
470 chronic viral hepatitis markers in 791 recent immigrants in Catalonia, Spain. Screening
471 and vaccination against hepatitis B recommendations]. *Rev Clin Esp* [Internet]. 2008 Oct
472 [cited 2018 Apr 26];208(9):426–31. Available from:
473 <http://www.ncbi.nlm.nih.gov/pubmed/19000469>
- 474 40. Cochrane A, Evlampidou I, Irish C, Ingle SM, Hickman M. Hepatitis B infection
475 prevalence by country of birth in migrant populations in a large UK city. *J Clin Virol*.
476 2015 Jul;68:79–82.
- 477 41. ©2009 Abbott Laboratories. ABBOTT PRISM Chagas assay Ref 7K35-68. (43).
- 478 42. © Vircell SL. Granada Spain. T1020: Prueba inmunoenzimática indirecta para
479 determinar anticuerpos IgG+IgM frente a Trypanosoma cruzi en suero humano.
480 2012;1–4.
- 481 43. World Health Organisation. Control of Chagas Disease: second report of the WHO
482 Expert Committee. Brasilia, Brazil; 2002.
- 483 44. © SCIMEDX CORPORATION. Strongyloides serology microwell ELISA. Dover;USA.
- 484 45. © 2014 Siemens Healthcare Diagnostics. Tarrytown NU. ADVIA Centaur® HBsAgII REF
485 10492138. 2014;1–18.
- 486 46. © 2014 Siemens Healthcare Diagnostics. Tarrytown NU. ADVIA Centaur® HBc Total REF
487 07566733. 2014;1–18.
- 488 47. © 2009 Siemens Healthcare Diagnostics Inc. Tarrytown NU. ADVIA Centaur® Anti-HBs2
489 (aHBs2). Vol. 2. 2012. p. 1–18.
- 490 48. © 2014 Siemens Healthcare Diagnostics. Tarrytown NU. ADVIA Centaur aHAVT® REF

- 491 05498862. 2014;1–18.
- 492 49. © 2014 Siemens Healthcare Diagnostics. Tarrytown NU. ADVIA Centaur® HCV REF
493 03438099. 2014;1–22.
- 494 50. © 2014 Siemens Healthcare Diagnostics. Tarrytown NU. ADVIA Centaur® HIV 1/O/2
495 Enhanced REF 01463908. 2014;1–22.
- 496 51. StataCorp. Stata Statistical Software: Release 15. Coll. Coll Station TX. 2017;(StataCorp
497 LLC).
- 498 52. Cortes G. Partir para quedarse. Institut français d'études andines; 2004.
- 499 53. Requena-Méndez A, Aldasoro E, de Lazzari E, Sicuri E, Brown M, Moore DAJ, et al.
500 Prevalence of Chagas Disease in Latin-American Migrants Living in Europe: A Systematic
501 Review and Meta-analysis. Rodrigues MM, editor. PLoS Negl Trop Dis [Internet]. 2015
502 Feb 13 [cited 2018 Feb 14];9(2):e0003540. Available from:
503 <http://www.ncbi.nlm.nih.gov/pubmed/25680190>
- 504 54. Dias JCP, Silveira AC, Schofield CJ. The impact of Chagas disease control in Latin
505 America: a review. Mem Inst Oswaldo Cruz [Internet]. 2002 Jul [cited 2019 Apr
506 11];97(5):603–12. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/12219120>
- 507 55. Alonso-Vega C, Alves F, Strub-Wourgaft N, Torrico F, Gascon J, Ortiz L, et al. Treatment
508 of adult chronic indeterminate Chagas disease with benznidazole and three E1224
509 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial. Lancet
510 Infect Dis [Internet]. 2018 [cited 2018 Dec 5];18:419–49. Available from:
511 <http://dx.doi.org/10.1016/>
- 512 56. Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG, et al. Long-term cardiac
513 outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a
514 nonrandomized trial. Ann Intern Med [Internet]. 2006 May 16 [cited 2018 May
515 20];144(10):724–34. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/16702588>
- 516 57. Murcia L, Simón M, Carrilero B, Roig M, Segovia M. Treatment of Infected Women of
517 Childbearing Age Prevents Congenital Trypanosoma cruzi Infection by Eliminating the
518 Parasitemia Detected by PCR. J Infect Dis J Infect Dis ® [Internet]. 2017 [cited 2018 Dec
519 7];215:1452–60. Available from: [https://academic.oup.com/jid/article-
520 abstract/215/9/1452/2993887](https://academic.oup.com/jid/article-abstract/215/9/1452/2993887)
- 521 58. Moscatelli G, Moroni S, García-Bournissen F, Ballering G, Bisio M, Freilij H, et al.
522 Prevention of congenital Chagas through treatment of girls and women of childbearing
523 age. Mem Inst Oswaldo Cruz, Rio Janeiro [Internet]. 2015 [cited 2018 Dec
524 7];110(4):507–9. Available from:
525 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4501414/pdf/0074-0276-mioc-110-4-
526 0507.pdf](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4501414/pdf/0074-0276-mioc-110-4-0507.pdf)
- 527 59. Fabbro DL, Danesi E, Olivera V, Codebó MO, Denner S, Heredia C, et al. Trypanocide
528 Treatment of Women Infected with Trypanosoma cruzi and Its Effect on Preventing
529 Congenital Chagas. Büscher P, editor. PLoS Negl Trop Dis [Internet]. 2014 Nov 20 [cited
530 2018 Dec 7];8(11):e3312. Available from: www.plosntds.org
- 531 60. Cruz S, Potosí B, Paz L. Bolivia Country Profile Health in the Americas 2007 [Internet].
532 2007 [cited 2018 Sep 10]. Available from: [https://www.paho.org/paho-
533 usaid/index.php?option=com_docman&view=download&alias=10285-bolivia-country-
534 profile-health-in-the-americas-2007&category_slug=hss-salud-en-las-](https://www.paho.org/paho-usaid/index.php?option=com_docman&view=download&alias=10285-bolivia-country-profile-health-in-the-americas-2007&category_slug=hss-salud-en-las-)

535 americas&Itemid=3505&lang=es

536

537 [Supporting Information Legends](#)

538 S1 Checklist: STROBE Checklist

539